Intestinal parasites, both protozoa and helminths, are 2 main enteric pathogens in developing countries, and some of these are responsible for emerging and reemerging infections in immunodeficient patients \[[@b1-kjp-54-3-339]-[@b5-kjp-54-3-339]\]. Sarcocystosis is an intracellular protozoan parasitic disease caused by coccidia of the genus *Sarcocystis* \[[@b6-kjp-54-3-339]\]. Since the first report of *Sarcocystis* infection, more than 120 species have been identified in this genus \[[@b6-kjp-54-3-339]\].

Depending on the species of *Sarcocystis*, these parasites are causative agents of intestinal or muscular sarcocystosis in human beings \[[@b6-kjp-54-3-339]\]. *Sarcocystis* protozoa of the intestinal tract in humans as the final host (excretion of sporocysts with feces) have a similar life cycle. In humans, infection occurs from eating uncooked or poorly cooked meat of some livestock with infective stages (sarcocysts) and the sexual phase (gametogony) occurs in the intestinal mucosa \[[@b6-kjp-54-3-339],[@b7-kjp-54-3-339]\]. In some countries, infection has potential public health importance, because humans may acquire infection by consumption of raw or undercooked beef or pork causing intestinal sarcocystosis \[[@b6-kjp-54-3-339]\]. For example, *Sarcocystis*-associated acute enteritis was reported in 6 cases in Thailand. *Sarcocystis* is not usually considered as an important enteric pathogen in immunocompromised patients but a report has been published on intestinal sarcocystosis-associated cholecystitis in Iran \[[@b8-kjp-54-3-339]\].

Although there are several reports about the prevalence of intestinal sarcocystosis in humans from different regions of the world, there is no published data about identified species causing intestinal infections using molecular methods in Iran. The primary aim of the present study was detection and differentiation of *Sarcocystis* oocysts and/or sporocysts from enteric protozoans in diarrheal samples of immunodeficient patients in Shiraz, Iran.

In this study, fecal samples were collected from 741 immunodeficient individuals (493 males and 248 females), including 387 patients with HIV/AIDS; 187 patients with malignancy, especially while on chemotherapy; 124 of those who had received either a solid organ or a bone marrow transplant; 43 individuals with prolonged corticosteroid therapy or hypogammaglobulinemia with recurrent persistent or chronic diarrhea from October 2009 to October 2014. The stool samples collected in clean plastic containers were transferred to the Laboratory of Intestinal Protozoology at Shiraz University of Medical Sciences.

Whenever possible, more than 1 fecal sample was collected from each patient. After recording the consistency of feces (watery or loose), color, gender, and age (aged 3-94) as well as underlying diseases, each sample was examined by direct wet mount, formalin-ethyl acetate concentration, and modified acid-fast or acid-fast trichrome stains. In the fecal samples containing *Sarcocystis*, sporocysts were floated using Sheather's sugar flotation procedure to harvest sporocysts from stool debris. To remove the sucrose solution and to prepare the sporocysts for lysis, the harvested sporocysts were diluted in 1 ml sterile tap water, centrifuged and washed in saline solution 2 times repeatedly. The washed sporocysts were stored at 4˚C until use for molecular studies.

For molecular identification, DNA was extracted from harvested sporocysts using proteinase K digestion, and phenol-chloroform purification followed by ethanol precipitation method as previously described. DNA extracted was then frozen at -20˚C until use for molecular studies. A fragment of the 18S rDNA gene was amplified using a semi-nested PCR procedure, as previously described \[[@b9-kjp-54-3-339]\] and reported in previous investigations in the laboratory \[[@b8-kjp-54-3-339]\]. The outer primers were *2L* (GGATAAACCGTGGTAATTCTATG) and 2H (ACCTGTTATTGCCTCAAACTTC) and the inner primers were *2L* and *3H* (GGCAAATGCTTTCGCAGTAG) \[[@b8-kjp-54-3-339],[@b9-kjp-54-3-339]\]. The templates were subjected to 30 amplification cycles (94˚C for 40 sec, 53˚C at primary PCR and 56˚C at secondary PCR for 60 sec, 72˚C for 100 sec at primary PCR and 80 sec at secondary PCR) followed by 1 cycle 7 min at 72˚C and held at 4˚C \[[@b8-kjp-54-3-339],[@b9-kjp-54-3-339]\]. Amplification product was analyzed by electrophoresis through a 2% agarose gel for the *Sarcocystis*-specific PCR. PCR product was directly sequenced with the set of primers *2L* and *3H* used for the secondary step. The sequence was compared with sequences in the GenBank database by BLAST analysis. For better understanding of relationship among *S. cruzi* and other species in the genus *Sarcocystis*, a phylogenetic analysis of 18S rDNA was performed using CLC Sequence Viewer 6 software (<http://www.clcbio.com>). *Neospora caninum* was used as the outgroup. All the microscopic-negative fecal samples were also ruled out using DNA extraction and the same primers \[[@b8-kjp-54-3-339],[@b9-kjp-54-3-339]\]. In addition to microscopic examinations, semi-nested PCR analyses were performed to confirm whether isolated oocysts were of other protozoans (e.g., *Cryptosporidium*, *Cystoisospora belli*, and *Cyclospora cayetanensis*), as previously reported \[[@b2-kjp-54-3-339]\].

Microscopic and PCR examinations on the patients' samples revealed oocysts of *Cryptosporidium* spp., *C. belli* (syn. *Isospora belli*), *C. cayetanensis*, and microsporidia (*Enterocytozoon bieneusi*) in 68, 9, 2, and 15 cases ([Fig. 1](#f1-kjp-54-3-339){ref-type="fig"}), respectively ([Table 1](#t1-kjp-54-3-339){ref-type="table"}). In addition, scanty sporulated sporocysts of *Sarcocystis* sp., each containing 4 sausage-shaped sporozoites and a mass of refractile granules called residual body were observed in the stool specimen collected from a patient ([Fig. 2A](#f2-kjp-54-3-339){ref-type="fig"}). Each sporocyst was ovoid in shape and measured 14.5-17.0×9-11 μm in size ([Fig. 2A](#f2-kjp-54-3-339){ref-type="fig"}).

The semi-nested PCR produced a \~850 bp amplicon ([Fig. 2B](#f2-kjp-54-3-339){ref-type="fig"}). Sequence of the PCR product was close to *S. cruzi* retrieved from GenBank. With these 2 findings, the sporocysts found from a patient were identified as those of *Sarcocystis cruzi*. Nucleotide sequence of this parasite was deposited in the GenBank database under accession no. KR136315. *Sarcocystis* DNA was not detected from any of microscopically negative samples.

*Sarcocystis*-positive diarrheal sample was from a woman with AIDS and a CD4^+^ count of less than 100 cells/μl. Prior to fecal microscopic examination in author's laboratory, she had a history of intermittent diarrhea that was variably associated with nausea, vomiting, loss of appetite, and weight loss for 6 months. As the patient had intermittently experienced this diarrhea, she had been previously undergone cholecystectomy, and repeated histopathological investigation of the gallbladder biopsy had demonstrated acalculous cholecystitis with non-specific inflammations. An ultrasound scan of the right upper quadrant had revealed thickening of the anterior portion of the gallbladder wall with no stones, pericholecystic fluid, or dilation of the bile ducts or gallbladder. During the last episode of diarrhea, the patient was referred to the author's laboratory where numerous oocysts of *Cystoisospora belli* and sporocysts of *Sarcocystis* were identified by parasitological stool examinations. The patient was treated with cotrimoxazole and showed improvements in 4 days.

Examples of immunodeficient individuals include those with AIDS, cancer, and transplant patients who are taking certain immunosuppressive drugs; and those with inherited diseases that affect the immune system (e.g., congenital IgA deficiency, congenital agammaglobulinemia). Although all of the enteric conventional pathogens can cause diarrhea in the immunodeficient host, these patients are at risk of developing infections with opportunistic parasites \[[@b10-kjp-54-3-339],[@b11-kjp-54-3-339]\]. The diagnostic workup of diarrhea in an immunocompromised or immunosuppressed host can be more difficult. For parasitic and coccidial infections, including *Cryptosporidium*, *C. belli*, *C. cayetanensis*, and microsporidia, special stains, including modified acid-fast, are needed.

Unfortunately, the diarrhea caused by these parasites cannot be differentiated from that caused by other enteric pathogens, such as enterotoxigenic *Escherichia coli*, *Giardia lamblia*, and viral agents (Norwalk and rotavirus) \[[@b10-kjp-54-3-339]\]. Identification of these parasites will help the proper therapy of these patients, because effective drugs are available for the treatment of most of these opportunistic infections \[[@b10-kjp-54-3-339]\].

Studies from some other regions of Iran, similar to what was found in our study ([Table 1](#t1-kjp-54-3-339){ref-type="table"}) demonstrated that cryptosporidiosis is a common opportunistic enteric protozoan disease encountered in HIV/AIDS-infected individuals with CD4^+^ counts \<200 cells \[[@b12-kjp-54-3-339]\]. Up to now, few researchers have reported *C. belli* infection in immunosuppressed patients in Iran \[[@b13-kjp-54-3-339],[@b14-kjp-54-3-339]\]. However; there is no report available on the prevalence of *C. belli* infection in Iran. The low prevalence of cystoisosporiasis and cyclosporiasis in Iran and especially in this research may be related to the secondary prophylaxis for pneumocystosis through the administration of cotrimoxazole during the course of AIDS and use of immunosuppressive agents for solid organ or bone marrow transplantation, since *C. belli* and *C. cayetanensis* are sensitive to this treatment. Very limited information is available on microsporidial infection from Iran. The prevalence of intestinal microsporidial infection depends on geographical area, diagnostic methods, and immune status of study population \[[@b15-kjp-54-3-339]\].

*Sarcocystis* species have global distribution. To date, humans are an intermediate host of some unknown *Sarcocystis* spp. and a definitive host of 2 known species, *Sarcocystis hominis* (syn. *S. bovihominis*) with a cattle-man cycle and *Sarcocystis suihominis* with a pig-man cycle \[[@b6-kjp-54-3-339],[@b7-kjp-54-3-339]\]. The standard method for diagnosing intestinal sarcocystosis is usually made by microscopically identifying typical *Sarcocystis* sporocysts each with 4 sporozoites in stool samples. Because parasites may be difficult to find in light infections, patients might need to submit several specimens collected on different days and a concentration procedure is recommended \[[@b6-kjp-54-3-339]\]. The prevalence of intestinal sarcocystosis in humans has been reported to be between 1.1% to 10.4% in some European countries, 0.5% in Australia, 0% in Argentina, and between 0.4% and 23.2% in Tibet and Thailand, respectively, although reports of human enteric infections with *Sarcocystis* are limited \[[@b10-kjp-54-3-339]\]. High prevalence rate of intestinal *Sarcocystis* infection in northern Thailand was likely due to risk factors, including the local habitat of eating raw or undercooked beef and pork, poor living conditions, and low levels of hygiene in Thai laborers \[[@b16-kjp-54-3-339]\]. Testing for intestinal sarcocystosis is not routinely done in most Iranian clinical laboratories, even when stool is tested for ova and parasites, so there are no data on the presence of intestinal sarcocystosis in Iranian individuals. In spite of high percentages of muscular sarcocystosis in slaughtered livestock in Iran, especially Fars province \[[@b17-kjp-54-3-339]-[@b23-kjp-54-3-339]\], the very low prevalence rate of *Sarcocystis* in this study is indicative of the religious habit of eating properly cooked beef in immunodeficient patients. Because of the Islamic prohibition on eating porcine, there is no pig farming in Iran, so the transmission of *Sarcocystis* through pork is very unlikely. Unlike the morphology of sarcocysts, differentiation of *Sarcocystis* species from one another is not possible only by morphology or size of sporocysts or oocysts, although the oval sporocysts belonging to cats measure about 12 μm and in dogs and humans about 15 μm \[[@b24-kjp-54-3-339]\].

The 18S ribosomal DNA region has been extensively used as a suitable target to differentiate *Sarcocystis* spp. and phylogenetic relationship among them \[[@b25-kjp-54-3-339]-[@b28-kjp-54-3-339]\]. The method used in this study for identification was achieved by 18S rDNA amplification, sequencing, and comparing with the key reference sequences of *Sarcocystis* species deposited in the GenBank. Comparing the molecular sequencing results of the sample obtained in the present study with those previously reported for different *Sarcocystis* spp. revealed the positive *Sarcocystis* sample as *S. cruzi*. The nucleotide sequence of *S. cruzi* obtained in this study was deposited in the GenBank database under accession no. KR136315. This sequence has 100%, 99%, and 97% homology compared to *S. cruzi* with accession nos. KT306829, AF176933, and KT306829, which are species using cattle and water buffaloes as intermediate hosts, respectively. The phylogenetic analysis based on CLC Sequence Viewer 6 software ([Fig. 3](#f3-kjp-54-3-339){ref-type="fig"}) indicated 5 distinct clades in the genus *Sarcocystis*. *S. cruzi* from the present study which was placed in a group with *S. cruzi* (accession no. KT306829) from Punjab, India. This group was adjacent to other groups containing 1 *S. tenella* and 2 *S. taeniata* sequences. This issue indicates that *S. tenella* and *S. taeniata* have the closest relationship with *S. cruzi* compared with other species in the genus *Sarcocystis*.

To the best of our knowledge, this is the first report of intestinal sarcocystosis caused by *S. cruzi* from a naturally infected human, an AIDS patient in Iran. It can be concluded that *Sarcocystis* species present in an enteric from of infection in humans are not restricted to the 2 previously established species, namely *S. hominis* and *S. suihominis*.
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![Modified Kinyoun's acid fast staining showing enteric protozoan oocysts. (A) *Cryptosporidium* species (4-6 μm). (B) *Cystoisospora belli* (32×16 μm). (C) *Cyclospora cayetanensis* (10 μm). (D) Spores (arrows) of microsporidia (*Enterocytozoon bieneusi*) (1.1-1.6×0.7-1.0 μm).](kjp-54-3-339f1){#f1-kjp-54-3-339}

![Identification of *Sarcocystis cruzi* sporocyst (arrow). (A) *Sarcocystis cruzi* sporocyst in an AIDS patient's diarrheal sample. 1 ocular unit=2.5 μm. (B) Agarose gel of semi-nested PCR products. Arrow indicates *Sarcocystis cruzi* DNA (\~850 bp). Lane M, 100 bp molecular size marker; lanes 1-2, microscopically-negative stool specimens; lane 3, *Cystoisospora belli* sample; lane 4, negative control; lane 5, this case.](kjp-54-3-339f2){#f2-kjp-54-3-339}

![A phylogenic tree of *Sarcocystis cruzi* (KR136315) with other *Sarcocystis* species. *S. cruzi* of this case is boxed. *Neospora caninum* was used as an outgroup. The relationships were inferred by phylogenetic analysis of partial 18S rDNA sequence data using CLC Sequence Viewer 6 software (<http://www.clcbio.com>). Accession no. of sequence is given in bracket. The scale bar indicates distance.](kjp-54-3-339f3){#f3-kjp-54-3-339}

###### 

Prevalence of enteric protozoan oocysts and microsporidia in diarrheic immunodeficient patients (n=741)

  Protozoa                    No. of positive samples (%)
  --------------------------- -----------------------------
  *Cryptosporidium* spp.      68 (9.2)
  *Cystoisospora belli*       9 (1.2)
  *Cyclospora cayetanensis*   2 (0.3)
  *Sarcocystis*^\*^           1 (0.1)
  Microsporidia               15 (2.0)
  Negative                    646 (87.2)

All samples were double examined by microscopy and semi-nested PCR \[[@b2-kjp-54-3-339], [@b3-kjp-54-3-339]\].
